U.S. FDA approves AbbVie all-oral hepatitis C treatment

(Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen, which will be sold under the brand name Viekira Pak, for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat. ...



via Health News Headlines - Yahoo News http://ift.tt/1AmtE4S